


## Yukon-Kuskokwim HEALTH CORPORATION

## **Treatment Protocol**

## Massive Transfusion Protocol (≥14 years)



| Risks of Massive Transfusion  | Availability of Blood Products at YKHC  |                  |          |
|---|---|------------------|----------|
| Non-fatal complications in 50% of patients transfused >5 units of   | Blood type                              | Quantity (units) | Rounds** |
| blood:<br>• Coagulopathy  | O negative                              | 10               | 2-3      |
| <ul> <li>Thrombosis</li> <li>ARDS: adult respiratory distress syndrome</li> <li>TACO: transfusion-associate circulatory overload</li> <li>TRALI: transfusion-related acute lung injury</li> <li>Hemolytic reaction</li> </ul> | O positive                              | 16               | 4-5      |
|   | A positive                              | 10               | 6-7      |
|   | B positive                              | 6                | 5-6      |
|   | AB                                      | none             | 7-8      |
| Tips  |   |                  |          |
| Avoid crystalloids to prevent dilution     Acidesis predicts matching. Tractment is to entirgize request tetter   | Anticoagulation Reversal Agents at YKHC |                  |          |

Acidosis predicts mortality. Treatment is to optimize resuscitation.
 No clear benefit to bicarb but may be considered if pH persistently
 7.2 despite resuscitation.

• Avoid hypothermia; keep core temperature > 36°C.

• pRBC should be transfused with a mass transfuser and blood warmer.

· Utilize ED technician to transport blood products during an MTP.

DOA/warfarin: Kcentra 2000 units or 25-50 units/kg at ~3
units/kg/minute

Warfarin: Vitamin K 2.5-10 mg IV over 10-20 minutes

Dabigatran: PraxBind<sup>®</sup> 2.5 grams IV Q5 minutes x2

• Heparin: Protamine 0.5-1 mg IV over 10 minutes

\*\*Per lab policy, the blood bank cannot dispense all units to a single patient in case of other emergencies. May discuss with Clinical Director on call.

This guideline is designed for the general use of most patients but may need to be adapted to meet the special needs of a specific patient as determined by the medical practitioner. Approved by Clinical Guideline Committee 11/21/23. Click here to see the supplemental resources for this guideline. If comments about this guideline, please contact Travis\_Nelson@ykhc.org.